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Abstract
Introduction Accurate and timely diagnosis of community-
acquired bacterial infections in patients with systemic
inflammation remains challenging both for clinician and
laboratory. Combinations of markers, as opposed to single ones,
may improve diagnosis and thereby survival. We therefore
compared the diagnostic characteristics of novel and routinely
used biomarkers of sepsis alone and in combination.
Methods This prospective cohort study included patients with
systemic inflammatory response syndrome who were suspected
of having community-acquired infections. It was conducted in a
medical emergency department and department of infectious
diseases at a university hospital. A multiplex immunoassay
measuring soluble urokinase-type plasminogen activator
(suPAR) and soluble triggering receptor expressed on myeloid
cells (sTREM)-1 and macrophage migration inhibitory factor
(MIF) was used in parallel with standard measurements of C-
reactive protein (CRP), procalcitonin (PCT), and neutrophils.
Two composite markers were constructed – one including a
linear combination of the three best performing markers and
another including all six – and the area under the receiver
operating characteristic curve (AUC) was used to compare their
performance and those of the individual markers.
Results A total of 151 patients were eligible for analysis. Of
these, 96 had bacterial infections. The AUCs for detection of a
bacterial cause of inflammation were 0.50 (95% confidence
interval [CI] 0.40 to 0.60) for suPAR, 0.61 (95% CI 0.52 to
0.71) for sTREM-1, 0.63 (95% CI 0.53 to 0.72) for MIF, 0.72
(95% CI 0.63 to 0.79) for PCT, 0.74 (95% CI 0.66 to 0.81) for
neutrophil count, 0.81 (95% CI 0.73 to 0.86) for CRP, 0.84
(95% CI 0.71 to 0.91) for the composite three-marker test, and
0.88 (95% CI 0.81 to 0.92) for the composite six-marker test.
The AUC of the six-marker test was significantly greater than
that of the single markers.
Conclusion Combining information from several markers
improves diagnostic accuracy in detecting bacterial versus
nonbacterial causes of inflammation. Measurements of suPAR,
sTREM-1 and MIF had limited value as single markers, whereas
PCT and CRP exhibited acceptable diagnostic characteristics.  
Trial registration NCT00389337
AUC = area under the receiver operating characteristic curve; CI = confidence interval; CRP = C-reactive protein; ICU = intensive care unit; MIF = 
macrophage migration inhibitory factor; PCT = procalcitonin; ROC = receiver operating characteristic; SIRS = systemic inflammatory response syn-
drome; SOFA = Sequential Organ Failure Assessment; suPAR = soluble receptors urokinase-type plasminogen activator; sTREM = soluble triggering 
receptor expressed on myeloid cells.Critical Care    Vol 11 No 2    Kofoed et al.
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Introduction
Bacterial infections and sepsis are major causes of morbidity
and mortality in medical departments and intensive care units
(ICUs) [1-3]. Accurate and timely diagnosis of infection
remains challenging to both clinician and laboratory. Clinical
and laboratory signs of systemic inflammation, including
changes in body temperature, tachycardia, respiratory rate
and leucocytosis, are sensitive. However, their use is limited by
poor specificity for the diagnosis of sepsis, because critically
ill patients often present with the systemic inflammatory
response syndrome (SIRS) but no infection [1,4-6]. These
issues have fuelled the search for a reliable marker. Many
potential biomarkers have been investigated, but only C-reac-
tive protein (CRP) and procalcitonin (PCT) are currently used
on a routine basis [7-10]. The search for a single magic bullet
marker might ultimately be fruitless, but a combination of mark-
ers could improve diagnosis, prognosis and treatment effi-
cacy, and thereby survival [7].
A recently discovered biomarker, soluble triggering receptor
expressed on myeloid cells (sTREM)-1, is known to be upreg-
ulated on phagocytic cells in the presence of bacteria or fungi
[11]. sTREM-1 has been found to be more sensitive and spe-
cific than both CRP and PCT in diagnosing sepsis in ICU
patients with SIRS [12,13]. The value of sTREM-1 in diagnos-
ing sepsis in settings other than the ICU remains to be deter-
mined. Another novel infectious disease biomarker is soluble
urokinase-type plasminogen activator receptor (suPAR). Con-
centrations of suPAR are increased in conditions that involve
immune activation, and studies have shown that high concen-
trations of suPAR portend a poor clinical outcome in diverse
infections such as tuberculosis, malaria and pneumococcal
bacteraemia [14,15]. Finally, the cytokine macrophage migra-
tion inhibitory factor (MIF) has been found to be a valuable
marker of microbiologically documented infection in patients
who have undergone cardiac surgery [16], and elevated MIF
concentrations may be an early indicator of poor outcome in
patients with sepsis [17]. The use of sTREM-1, suPAR and
MIF to diagnose community-acquired bacterial infections in
medical patients has not yet been studied.
We undertook the present study to determine the discrimina-
tive power of combining multiple markers to diagnose bacterial
infections in adult medical patients admitted to a hospital who
are suspected of having community-acquired infections.
Materials and methods
Participants
This prospective observational study was conducted from
February 2005 to February 2006 at an 800-bed university
hospital. All consecutive newly admitted (< 24 hours) adult
patients (age ≥ 18 years), who fulfilled at least two criteria for
SIRS [6] and who were admitted to the Department of Infec-
tious Diseases or the infectious disease unit in Medical Emer-
gency Department, were asked to participate.
The principal investigator and study nurses recruited patients
and collected data on two daily rounds on each week day.
Based on data obtained during week days, it was estimated
that during the entire study period about 1,800 patients were
admitted to the Department of Infectious Diseases from home
and that 33% of admitted patients fulfilled at least two SIRS
criteria. Of these, 59% were ineligible to participate for the fol-
lowing reasons: admission > 24 hours before evaluation or
referral from other departments/hospitals (24%), failure to pro-
vide informed written consent (22%), age under 18 years
(5.2%), refusal to participate (2.6%), and other reasons (for
instance, communication problems; 3.7%). All evaluable
patients were included in the main analysis.
The only protocol-driven procedures were blood sampling,
collection of data for later calculation of admission Simplified
Acute Physiology Scale II and Sequential Organ Failure
Assessment scores [18,19], and daily recording of tempera-
ture, pulse rate, blood pressure and respiratory rate over one
week. Mortality rates at 30 days and 6 months after inclusion
were recorded by accessing the Danish Civil Registration Sys-
tem and patient charts. Blood was drawn from a cubital vein
into Vacutainer tubes (Becton Dickinson, Plymouth, UK)
directly after patient inclusion. The sampling followed routine
hospital procedures and was performed by biotechnicians.
Plasma from one 6 ml K2-EDTA coated tube was separated by
centrifugation and stored at -20°C for up to one week and then
transferred to -80°C for later analysis of PCT, suPAR, sTREM-
1 and MIF.
The Scientific Ethical Committee of Copenhagen and Freder-
iksberg Communes approved sample collection on the basis
of informed written consent (KF01-108/04). The study proto-
col is registered on the internet (NCT00389337) [20].
Reference standard
All patients were grouped into one of the following four
groups: no infection present, bacterial infection, viral infection,
or parasitic infection. Classification was based on clinical find-
ings, on laboratory findings, response to treatments, radio-
graphic and other imaging procedures, and both positive and
negative bacteriological, viral and parasitic findings (including
culture, polymerase chain reaction, serological and antigen
tests performed) during the first seven days of admission. An
expert panel consisting of two infectious disease specialists
(OA and GK) retrospectively reviewed all medical records per-
taining to each patient and independently decided on the diag-
nosis at the time of admission. The precise weighting of each
finding was greatly dependent on the disease diagnosed (for
instance, chest radiography in the diagnosis of respiratory
tract infections and cerebrospinal fluid cell counts in the case
of viral meningitis). Disagreement among reviewers was dis-
cussed, and agreement was reached by consensus. The panel
was blinded to PCT, suPAR, sTREM-1 and MIF values, and
was instructed to disregard CRP levels and neutrophil counts.Available online http://ccforum.com/content/11/2/R38
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Test methods
Duplicate measurements of plasma suPAR, sTREM-1 and MIF
were performed using a Luminex (Luminex corp. Austin, TX,
USA) multiplex assay, as described in detail previously [21].
Margins of error for suPAR, sTREM-1 and MIF measurements
are 10%, 12% and 13%, respectively. PCT plasma concentra-
tions were measured using an automated sandwich immu-
noassay based on the TRACE (time-resolved amplified
cryptate emission) technique, in accordance with the manu-
facturer's protocol (Kryptor; Brahms Diagnostica, Berlin-Hen-
ningsdorf, Germany). CRP was measured in plasma by
standard densiometry (Vitros 950 IRC; Johnson & Johnson,
Clinical Diagnostics Inc., Rochester, NY, USA). Margins of
error for both the PCT and CRP assays are 10%. Blood leu-
cocyte and neutrophil counts were measured using the Avida
120 device (Bayer Diagnostics, Tarrytown, NY, USA). Margins
of error for these measures were 3.3% and 4.8%, respectively.
The principal investigator conducted the Luminex multiplex
assay; the Kryptor assay was conducted by one laboratory
technician; and the CRP and leucocyte assays were con-
ducted by the hospital laboratory technicians who were on
duty when patients were enrolled in the study.
Before the study we chose to use cutoff values of 60 mg/l,
0.25 μg/l and 7.5 × 109 cells/l for CRP, PCT and neutrophils,
respectively. The cutoffs were based on previously reported
findings from cohorts similar to the present one [22-25]. Opti-
mal sTREM-1, suPAR, MIF, and three-marker and six-marker
cutoff values were determined using Youdens Index [26],
because of a lack of reference literature. Laboratory parame-
ters included in the Simplified Acute Physiology Scale II and
Sequential Organ Failure Assessment scores were analyzed
at the Department of Clinical Biochemistry, Copenhagen Uni-
versity hospital, Hvidovre, Denmark and followed routine
procedures.
Statistics
Measurements of suPAR, sTREM-1, MIF, CRP and PCT were
transformed using the logarithmic function in order to obtain
normality of distribution within disease groups. Neutrophil
count was not transformed. The Mann-Whitney U-test was
used to compare concentrations of all single markers in
patients with documented bacterial infections with those in
patients who had undocumented bacterial infections. Sensitiv-
ities and specificities with precise 95% confidence intervals
(CIs) were calculated for all single and composite markers
[27]. Information from the three single best performing mark-
ers and all six markers were combined using the method
reported by by Xiong and coworkers [27], that is, by identifying
the linear combination of markers that yielded the greatest
area under the receiver operating characteristic (ROC) curve
(AUC). This led to the construction of a composite three-
marker test and a composite six-marker test optimized to dif-
ferentiate between bacterial and nonbacterial causes of
inflammation. Standard errors of the AUCs were obtained
using the method reported by Xiong and coworkers [27],
based on Fisher's Z transformation. The diagnostic perform-
ances of the composite markers were compared with the per-
formances of all singles marker using the AUC, in accordance
with by the method suggested by Hanley and McNeil [28]. All
tests were two sided, and P < 0.05 was considered statisti-
cally significant. Data were analyzed using the statistical pack-
age R version 2.3.1 (R Development Core Team, Vienna,
Austria). Figures were drawn using GraphPad Prism version
4.01 (GraphPad Software, San Diego, CA, USA).
Results
A total of 161 patients fulfilling at least two SIRS criteria were
included in the study. Because of exceeded time limits
between admission and the index test, non-evaluable samples,
missing data and withdrawal of consent, 10 patients were sub-
sequently excluded. For the remaining 151 patients, clinical
and demographic characteristics, comorbidity and antibiotic
treatment before admission are summarized in Table 1.
The expert panel classified 117 patients as infected: 96 with a
bacterium, 16 with a virus and five with a parasite. From all but
three patients, blood cultures were obtained at admission. A
pathogenic bacterium was isolated from blood in 22 patients
(15%). At admission and during the first seven days in the hos-
pital, additional cultures were conducted in urine from 96
(64%), sputum from 57 (38%), swabs (skin, wound, or
mucosal) from 22 (15%), stools from 19 (13%), and cerebro-
spinal fluid from 13 (8.6%) patients. A clinically relevant path-
ogen was isolated from 74 (49%) of the patients. Primary sites
of infection and pathogens isolated are summarized in Table 2.
All 19 patients classified as having a bacterial infection in the
respiratory system in the absence of microbial documentation
had chest radiograph findings suggestive of bacterial infec-
tion. In the 34 patients classified as non-infected, the causes
of SIRS were respiratory distress (lung oedema, chronic
obstructive pulmonary disease (COPD) exacerbation with no
signs of infection, and embolus of the lung; (n = 8), malignant
disease (n = 8), intracranial haemorrhage (n  = 2), allergic
reaction (n = 2), metabolic acidosis (n = 2), noninfectious pan-
creatitis (n = 1), gout (n = 1), use of impure intravenous drugs
(n = 1), ruptured mitral valve chordae (n = 1), ruptured tho-
racic aneurism (n = 1), Castleman's disease (n = 1), Addison's
disease (n = 1), subileus (n = 1) and polymyositis (n = 1).
Finally, in three patients no explanation for SIRS was found.
There was disagreement among reviewers in 11 cases; by
consensus, seven of these were classified as non-infected,
two as bacterial infection and two as viral infection.
We compared concentrations of the various markers between
the 64 patients with documented bacterial infection and the
32 patients classified as having bacterial infection of unknown
origin. The respective median concentrations were as follows:
175 and 157.5 mg/l (P = 0.70) for CRP, 0.96 and 0.87 μg/l
(P = 0.26) for PCT, 11.0 and 10.6 × 109 cells/l (P = 0.81) forCritical Care    Vol 11 No 2    Kofoed et al.
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neutrophils, 2.4 and 2.3 μg/l (P = 0.77) for suPAR, 7.9 and
8.5 μg/l (P = 0.36) for sTREM-1, and 1.4 and 1.3 μg/L (P =
0.86) for MIF. Recruitment, exclusion and subsequent group-
ing of all patients included in the study are shown in Figure 1.
A total of 120 patients (79%) were given antibiotics during the
first 24 hours of hospitalization: 64% of the patients with
inflammation of nonbacterial origin and 90% of the patients
with a bacterial infection. Six patients without a bacterial infec-
tion (11%) and three (3.1%) with a bacterial infection died
before day 30 after admission. After six months, 11 (20%)
patients who did not have a bacterial infection and eight
(8.3%) patients who did have a bacterial infection had died.
Individual baseline values and median levels of the six biomar-
kers are shown in Figure 2. The computed specificities, sensi-
tivities, positive and negative predictive values, and AUCs of
the single markers and the composite markers with regard to
diagnosis of bacterial infection are shown in Table 3. The cor-
responding ROC curves are shown in Figure 3. The six-marker
test performed significantly better than all of the single markers
(P = 0.010 for CRP and P < 0.001 for the five remaining mark-
ers). Additional analysis of the ability of single markers to dis-
criminate between infection of any kind and no infection
identified AUCs of 0.80 (95% CI 0.71–0.86) for CRP, 0.77
(95% CI 0.67–0.84) for PCT, 0.68 (95% CI 0.57–0.76) for
neutrophils, 0.59 (95% CI 0.48–0.70) for MIF, 0.56 (95% CI
0.45–0.67) for sTREM-1 and 0.51 (95% CI 0.40–0.63) for
suPAR.
It was apparent from Figure 2 that patients with a parasitic
(Plasmodium falciparum) infection had high concentrations of
CRP and PCT in particular, and so the effect of omitting these
patients on the AUCs for these two markers was determined.
This analysis identified AUCs of 0.83 (95% CI 0.76–0.90) and
0.77 (95% CI 0.69–0.85) for CRP and PCT, respectively, with
regard to discrimination between bacterial and nonbacterial
causes of inflammation. Several of the markers may be
Table 1
Baseline characteristics
Characteristic Patients (%; n = 151)
Age (years; median [range]) 56 (20–94)
Sex
Male 73 (48.3)
Female 78 (51.7)
Comorbiditya 67 (44.7)
Solid tumours and haematological malignancies 14 (9.3)
HIV infection 17 (11.3)
Diabetes 13 (8.6)
COPD and asthma 15 (9.9)
Drug or alcohol abuse 13 (8.6)
Other diseasesb 17 (11.3)
Medication before admission
Bacterial antibiotics 39 (25.8)
Immunosuppressivesc 9 (6.0)
Disease severity
SAPS II (median [5th to 95th percentile]) 18 (6–36)
SOFA score
0–1 86 (57.0)
2–3 48 (31.8)
4–5 12 (7.9)
>5 5 (3.3)
Data are expressed as n (%), unless otherwise indicated. aSeveral patients had more than one comorbidity (for eample, three had both HIV 
infection and viral hepatitis). bInflammatory bowl disease, rheumatoid arthritis, disseminated sclerosis, chronic adrenal insufficiency, viral hepatitis, 
cardio vascular diseases, and diseases of the thyroid gland. cSteroids, methotrexate, azathioprine, and monoclonal tumour necrosis factaor-α 
antibodies. COPD, chronic obstructive pulmonary disease; SAPS, Simplified Acute Physiology Score; SOFA, Sepsis-related Organ Failure 
Assessment.Available online http://ccforum.com/content/11/2/R38
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affected by immune-deficient conditions, and therefore an
ancillary analysis was conducted in which 38 patients with
solid tumours, haematological malignancies, HIV infection, leu-
cocyte counts below 1 × 109 cells/l, or treated with an immu-
nosuppressant were excluded. In this analysis the ability of the
markers to diagnose bacterial infections remained virtually
unchanged. None of the single marker AUCs changed by
more than 0.04 (data not shown).
To investigate the diagnostic accuracy of the six single mark-
ers and the two composite markers in a relevant subgroup, an
analysis of the 57 patients diagnosed as having COPD or
asthma with acute exacerbation or pneumonia (excluding
Mycobacterium tuberculosis infection) was performed. With
respect to the diagnosis of bacterial infection we obtained
AUCs of 0.94 (95% CI 0.87–1.00) for the six-marker test,
0.88 (95% CI 0.78–0.97) for the three-marker test, 0.88 (95%
CI 0.79–0.97) for CRP, 0.79 (95% CI 0.67–0.91) for PCT,
0.76 (95% CI 0.62–0.91) for sTREM-1, 0.72 (95% CI 0.56–
0.89) for neutrophils, 0.66 (95% CI 0.47–0.85) for MIF and
0.54 (95% CI 0.34–0.74) for suPAR.
In addition, the ability of single markers to predict culture-
proven bacteraemia was tested. The three markers with the
greatest AUCs were PCT, CRP and MIF, with AUCs of 0.84
Table 2
Site of infection and pathogens isolated
Site of infection (n)a Pathogens isolated (n)a
Respiratory system (58) Streptococcus pneumonia (14), Legionella pneumonia (4), Mycobacterium tuberculosis (3), 
Haemophilus influenza (3), Moraxella catarrhalis (2), Mycoplasma pneumonia (2), Pseudomonas 
aeruginosa (1), Chlamydia psittaci (1), Escherichia coli (1), Streptococcus haemolytica group A 
(1), varicella zoster virus (1), coronavirus (1), unknown bacterialb (19), unknown viralb (5)
Urinary tract (25) Escherichia coli (19), Streptococcus haemolytica group G (1), unknown bacterialb (5)
Gastrointestinal tract (16) Campylobacter jejuni (3), Salmonella enteritidis (2), Bacteroides fragilis (1), Salmonella dublin (1), 
Salmonella typhi (1), Streptococcus haemolytica group C (1), rotavirus (1), unknown bacterialb (4), 
unknown viralb (2)
Skin/soft tissue and bone/joint infection (8) Streptococcus haemolytica groups B and G (2), Staphylococcus aureus (1), unknown bacterialb 
(4), unknown viralb (1)
Cenral nervous system (5) Neisseria meningitidis (1), Streptococcus pneumoniae (1), unknown viralb (3)
Miscellaneous (9) Trepomena palidum (1), Enterococcus gallinarum (1), Plasmodium falciparum (5), Epstein-Barr 
virus (2)
Data are expressed as number of patients (in parenttheses). a Four patients had two sites of infection; two had pneumonia and urinary tract 
infection, one had meningitis and pneumonia, and one had staphylococcal skin infection and malaria. bClassified by two specialists in infectious 
diseases based on typical clinical presentation, anamnesis, chest radiography and other imaging, and cell counts from culture-negative pleura 
fluid, urine, and cererospinal fluid. Consensus was achieved in all cases.
Figure 1
Flowchart of the patients included in the study Flowchart of the patients included in the study. Flowchart describing the number of patients included in the study, the reasons for subsequent exclu-
sions, the final diagnoses of the patients, and the ability C-reactive protein (CRP), procalcitonin (PCT), and the three-marker and six-marker com-
bined tests to correctly diagnose patients as having bacterial infection. Optimal cutoffs for bacterial infection (determined by Youdens Index) were 
used for all four markers. SIRS, systemic inflammatory response syndrome.Critical Care    Vol 11 No 2    Kofoed et al.
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(95% CI 0.70–0.92), 0.69 (95% CI 0.54–0.80) and 0.61
(95% CI 0.46–0.72), respectively.
Discussion
In the present study, we demonstrate that there is a significant
gain in discriminative power of diagnostic sepsis markers
when the linear combination that yields the highest AUC is
employed. In addition, in patients admitted to a medical emer-
gency department or a department of infectious diseases, we
found that sTREM-1, MIF and suPAR as single markers have
limited diagnostic power to discriminate between bacterial
and nonbacterial causes of inflammation. However, if they are
combined with CRP, PCT and neutrophil count a high AUC of
0.88 is achieved.
The majority of studies of new sepsis biomarkers examine
these biomarkers one at a time. Measurements of plasma con-
centrations of each putative marker with individual assays
carry considerable burdens in terms of time, cost and sample
volume, thus limiting ability to examine systematically the
potential of multiple markers in combination. However, xMAP
technology provides the possibility to quantify multiple pro-
teins simultaneously in a solution phase using flow cytometry
[21]. This allows the researcher to profile multiple markers for
diagnostic and prognostic purposes simultaneously, and to
monitor changes over time in the markers to evaluate the effi-
cacy of treatment.
Having techniques to measure multiple markers simultane-
ously and being presented with a complex diagnostic chal-
lenge such as sepsis raises another question; how does one
optimally combine information from multiple markers? The
power of combining multiple sepsis markers is recognized, but
earlier studies used informal and suboptimal quantitative
approaches to identify the optimal combination. Several statis-
tical studies have addressed the problem of combining corre-
lated diagnostic tests to maximize discriminatory power. These
include logistic regression and linear and nonlinear discrimi-
nate analyses to identify the linear combination of markers that
yield the greatest AUC [29,30]. These models derive a score
but not a specific decision rule, as decision trees, Bayesian
decision making and neural networks do [4,27,29,31-35].
The combination of diagnostic markers appears a useful
approach to improving accuracy in diagnosing sepsis in
patients with SIRS and may be applicable to other complex
diseases as well. Use of ROC curves and comparison of
AUCs for single markers has become widespread; however,
although the statistical techniques needed to identify the com-
bination of ROC curves from multiple markers that yield the
greatest AUC have been available for some years, there use
has been limited. Only few studies have applied the statistical
techniques developed by Su and Liu [27,34]. These found
increased accuracy when diagnostic test were combined to
diagnose Alzheimer's disease and prostate cancer,
respectively.
Table 3
Accuracy of the six inflammatory markers and the combined three-marker and three-marker tests in diagnosing bacterial infection 
in SIRS patients
Biomarker Sensitivity (95% CI)a Specificity (95% CI)a AUC (95% CI) Specificity = 0.7 Specificity = 0.8 Positive 
predictive 
valueb
Negative 
predictive 
valueb
Sensitivity (95% CI) Sensitivity (95% CI)
CRP 0.86 (0.78–0.93) 0.60 (0.46–0.73) 0.81 (0.73–0.86) 0.72 (0.62–0.81) 0.67 (0.56–0.76) 0.79 0.73
PCT 0.80 (0.71–0.88) 0.58 (0.44–0.71) 0.72 (0.63–0.79) 0.69 (0.58–0.78) 0.51 (0.41–0.61) 0.80 0.63
Neutrophil count 0.74 (0.64–0.82) 0.64 (0.50–0.76) 0.74 (0.66–0.81) 0.70 (0.60–0.79) 0.59 (0.49–0.69) 0.82 0.57
MIF 0.80 (0.71–0.88) 0.47 (0.34–0.61) 0.63 (0.53–0.72) 0.41 (0.31–0.51) 0.29 (0.20–0.39) 0.73 0.58
sTREM-1 0.82 (0.73–0.89) 0.40 (0.27–0.54) 0.61 (0.52–0.71) 0.36 (0.27–0.47) 0.32 (0.23–0.43) 0.71 0.56
suPAR 0.35 (0.26–0.46) 0.67 (0.53–0.79) 0.50 (0.40–0.60) 0.31 (0.22–0.42) 0.23 (0.15–0.33) 0.65 0.37
3-markerc 0.67 (0.56–0.76) 0.89 (0.78–0.96) 0.84 (0.71–0.91) 0.76 (0.66–0.84) 0.70 (0.60–0.79) 0.91 0.60
6-markerd 0.88 (0.79–0.93) 0.78 (0.65–0.88) 0.88 (0.81–0.92) 0.89 (0.80–0.94) 0.84 (0.76–0.91) 0.88 0.78
aSensitivity and specificity of C-reactive protein (CRP), procalcitonin (PCT) and neutrophil count were computed using the predefined cutoff 
values of 60 mg/l, 0.25 μg/l and 7.5 × 109 cells/l, respectively. Sensitivity and specificity of macrophage migration inhibitory factor (MIF), soluble 
triggering receptor expressed on myeloid cells (sTREM)-1, soluble urokinase-type plasminogen activator receptor (suPAR), and the three-marker 
and six-marker tests were computed using optimal cutoff values determined using Youdens Index. bPositive and negative predictive values were 
calculated using Youdens Index-determined optimal cutoffs for all markers. The optimal cutoffs were 59 mg/l for CRP, 0.28 μg/l for PCT, 8.5 × 
109 cells/l for neutrophil count, 0.81 μg/l for MIF, 3.5 μg/l for sTREM-1, 2.7 μg/l for suPAR, 6.1 for the three-marker test and 4.1 for the six-marker 
test. cThree-marker test = 0.160 × neutrophil count + 0.981 × log(CRP) + 0.107 × log(PCT). dSix-marker test = -0.551 × log(suPAR) + 0.254 × 
log(sTREM-1) + 0.416 × log(MIF) + 0.098 × neutrophils + 0.639 × log(CRP) + 0.201 × log(PCT). AUC, area under the receiver operating 
characteristic curve; CI confidence interval.Available online http://ccforum.com/content/11/2/R38
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However, it is important to remember that the hunt for a larger
AUC might not always be clinically relevant. This is the case if
the gain is associated with very low sensitivity or specificity, as
was observed in our study, in which the sensitivity of PCT at
the predefined clinically relevant specificities was second
highest; only the six-marker test had higher sensitivity. In com-
parison the AUC of PCT was lower than both the AUCs of the
six-marker test, the three-marker test and CRP.
Promising results with sTREM-1 as a diagnostic sepsis marker
were reported over recent years [12,13,36]. Gibot and cow-
orkers [13] measured sTREM-1 in plasma samples from ICU
patients with SIRS suspected of having an infection; they
found that sTREM-1 was able to diagnose infection with a sen-
sitivity of 96% (95% CI 92–100%) and a specificity of 89%
(95% CI 82–95%). There were large difference between the
two patient cohorts, both in terms of spectrum and severity of
disease. It is known from previous studies that the diagnostic
accuracies of several sepsis markers are highly dependent on
the setting in which they are tested. Based on data from these
studies, it seems that PCT, in particular, exhibits superior per-
formance to that of CRP when it is used in an ICU; this might
as well be the case for sTREM-1 [3,9,13,22,25,37-43]. In
addition, different analytical methods, plasma anticoagulants,
and plasma sampling and processing procedures were used
[12,21]. In this regard we have shown that the half-life of
sTREM-1 in plasma is short (1.5 hours), and so our handling
procedures in the present study might have been too slow
[21]. Recently published findings on plasma sTREM-1 in
patients with pneumonia, COPD and asthma in a setting simi-
lar to ours indicate no difference in admission levels of sTREM-
1 between COPD and pneumonia patients, although the AUC
for guidance of antibiotic therapy was found to be 0.77 (95%
CI 0.70–0.84) [44], which is almost identical to the AUC of
0.76 (95% CI 0.62–0.91) achieved in our subgroup analysis.
Other interesting findings are that in patients with inflammatory
bowel disease a 400-fold increase in sTREM-1 concentration
was observed in those with severe disease as compared with
patients with only mild symptoms [45]. Also, in a murine air-
pouch model of crystal-induced acute inflammation, monoso-
dium urate monohydrate crystals induced high concentrations
of sTREM-1 [46]. Based on the present data on sTREM-1 as
Figure 2
Plasma concentrations of the markers Plasma concentrations of the markers. Shown are individual admission plasma concentrations of (a) C-reactive protein (CRP), (b) procalcitonin 
(PCT), (c) neutrophil count, (d) soluble urokinase-type plasminogen activator receptor (suPAR), (e) soluble triggering receptor expressed on mye-
loid cells (sTREM)-1 and (f) macrophage migration inhibitory factor (MIF) in patients with no infection (circle), bacterial (triangle, apex up), viral (trian-
gle, apex down), or parasitic infection (square). Bars represent the medians of the concentrations.Critical Care    Vol 11 No 2    Kofoed et al.
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a marker of infection, it seems reasonable to conclude that
more studies, using the same meticulously validated assay and
in more clinically relevant patient groups, are needed.
Studies investigating the use of PCT and CRP in medical and
emergency departments have found the diagnostic perform-
ance of CRP and PCT to be similar to those observed in our
study [22,25,37]. With regard to diagnosing bacteraemia in
particular, PCT exhibited excellent diagnostic ability; this is in
accordance with the suggested notion that PCT is superior to
CRP in diagnosing systemic infection [22,37,47,48]. The low
diagnostic accuracy of PCT in diagnosing bacterial infection
observed in our study was partly due to the five patients
infected with P. falciparum, as was shown in the analysis in
which this group was omitted.
Despite our study's strengths, however, several limitations
deserve consideration. It is probably an oversimplification to
use a linear model to combine markers. Quadratic or cubic
transformations of the biomarkers might improve diagnostic
accuracy. Because we used clinical criteria and microbiologi-
cal evidence, it might have been difficult to ascertain the
precise cause of SIRS in all patients, and this might have intro-
duced some misclassification bias. The expert panel disre-
garded measurements of leucocytes and CRP, but – as in
most studies on diagnostic sepsis markers – total blinding was
not achievable, because these measurements are an
integrated part the routine monitoring of infectious disease
patients and the values are reflected in the way in which the
patient is treated. This might have lead to incorporation bias
and thus an overestimation of the diagnostic power of these
two markers as compared with the other markers tested,
although this was not reflected in any statistically significant
differences in the concentrations of any of the markers in the
patients with 'known' versus 'unknown' bacterial infection.
Thus, it seems that no marker was afforded preferential condi-
tions by the classification. The fact that not all samples were
collected before antibiotic therapy was initiated might weaken
the results, because markers with short half-life would be more
affected than markers with long half-life. Patients with demen-
tia or other mental diseases could not participate in this study
(because of the need for informed written consent), and so it
is not know whether the results are valid for this important
group of patients. Finally, our results may apply only to patients
with community-acquired infections, which do not require hos-
pitalization in an ICU directly at admission, and so they may not
be valid in ICU patients.
Conclusion
Our results demonstrate that combining information from sev-
eral sepsis markers is simple and may significantly improve cli-
nicians' ability to differentiate patients with bacterial infections
from those with systemic inflammation of nonbacterial origin
when they are admitted. This would be of great importance in
patients in whom diagnosis is not clinically clear cut, as is often
the case in a specialized department of infectious diseases,
bearing in mind that rapid and adequate treatment of patients
suspected of having bacterial sepsis requires accurate
diagnosis.
Figure 3
ROC curves comparing markers' ability to detect bacterial infections in  patients with systemic inflammation ROC curves comparing markers' ability to detect bacterial infections in 
patients with systemic inflammation. Receiver operating characteristic 
(ROC) curves comparing soluble urokinase-type plasminogen activator 
receptor (suPAR), soluble triggering receptor expressed on myeloid 
cells (sTREM)-1, macrophage migration inhibitory factor (MIF), neu-
trophil count, procalcitonin (PCT), C-reactive protein (CRP), and the 
combined three-marker and six-marker tests for detection of bacterial 
versus nonbacterial causes of systemic inflammation.
Key messages
￿  Combining information from several markers appears to 
improve diagnostic accuracy for detection of bacterial 
versus nonbacterial causes of systemic inflammation.
￿  In a cohort of patients with SIRS, admitted to a medical 
emergency department or a department of infectious 
diseases and suspected of having community-acquired 
infections, single measurements suPAR, sTREM-1 and 
MIF appear to have limited power as diagnostic markers 
for bacterial infection.
￿  CRP, PCT and neutrophil count have acceptable diag-
nostic power for the diagnosis of community-acquired 
bacterial infection in patients with SIRS admitted to a 
department of infectious diseases.
￿  The diagnostic accuracy of CRP, PCT, sTREM-1, and 
the six-marker test was higher in the subgroup of 
patients suspected of having pneumonia than in the 
group as a whole.Available online http://ccforum.com/content/11/2/R38
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